The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

Melanotan II Dosage Guide

Melanotan II (MT-II) is a synthetic analogue of alpha-MSH. It is not approved by any regulatory agency, and health authorities including the FDA, EMA, and TGA have issued warnings about cardiovascular effects, severe nausea, and changes to moles/nevi that may indicate melanoma risk. Research use only. Research focuses on skin pigmentation and sexual function (via MC4R activation).

Standard Research Dosage

Tanning/pigmentation research: 0.5–1 mg subcutaneously, 3–5x per week. Sexual function research: 0.025 mg/kg body weight. Starting doses should be low (0.25 mg) to assess tolerability before escalation.

Receptor Targets

MT-II activates MC1R (pigmentation), MC3R (energy homeostasis), MC4R (sexual function, appetite), and MC5R (exocrine gland function). The broad receptor profile accounts for both desired effects and side effects.

Safety and Regulatory Warnings

FDA, EMA, and TGA have issued warnings about Melanotan II. Reported adverse effects include severe nausea, cardiovascular effects (blood pressure changes, tachycardia), and changes to moles/nevi with potential melanoma risk. MT-II is not approved for human use anywhere in the world. These risks are not dose-dependent in all cases.